Biotech "Tweets of the Week"
Early Spring Double Edition
(February 29 - March 11, 2016)
Featuring:
$ACAD $BIIB $BLUE $CLDX $EDIT $JUNO $KITE $SRPT $VRX $ZFGN
$XBI $IBB $LABU
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
Shoes keep dropping at Valeant as CEO returns $VRX
$VRX says Pearson returning as CEO after illness, effective immediately, reschedules earnings call https://t.co/b6pAyfoySZ
— Meg Tirrell (@megtirrell) February 29, 2016
$VRX non-deal roadshow today via UBS has also been cancelled.
— Andy Biotech (@AndyBiotech) February 29, 2016
Valeant's Addyi Provides Good Sex Every Other Month, Study Finds https://t.co/9Qgj6f1ZWJ via @business
— Charley Grant (@CGrantWSJ) February 29, 2016
Scoop: Valeant *will* hold a call today with CEO Mike Pearson after all (if you got invited) $VRX https://t.co/FfCDePSN9h
— Drew Armstrong (@ArmstrongDrew) February 29, 2016
Moody's reviews $VRX debt ratings for downgrade, citing concerns underlying performance weaker than expected: https://t.co/fWINwiuymE
— Meg Tirrell (@megtirrell) February 29, 2016
Hearing $VRX has now cancelled analyst call due to media interest
— Meg Tirrell (@megtirrell) February 29, 2016
First days back at work are always tough. $VRX
— Joe Weisenthal (@TheStalwart) February 29, 2016
You know it's bad when your PR has to make a distinction between a new SEC investigation and another one already underway. $vrx
— 23aloha (@23aloha) February 29, 2016
Valeant is now down 75% from its record high in August. At $65.80, $VRX closes at three-year low.
— Steven Russolillo (@srussolillo) February 29, 2016
It’s ridiculous that companies think that it’s okay to wait for the following 10K to disclose a formal SEC investigation/subpoena.
— Brad Loncar (@bradloncar) February 29, 2016
$VRX Deb Jorn has resigned. She ran dermatology and gastrointestinal businesses -- via @business
— Caroline Chen (@CarolineYLChen) March 3, 2016
$VRX appoints three new directors (as widely reported yesterday was the plan) https://t.co/IJxBiwYj03
— Meg Tirrell (@megtirrell) March 9, 2016
$VRX Valeant and R&O Pharmacy end litigation pursuant to a confidential settlement agreement <-- The lawsuit that opened the Pandora's box…
— Andy Biotech (@AndyBiotech) March 9, 2016
*HOUSE OVERSIGHT CMTE LEADERS SAY VALEANT WITHHOLDING DOCUMENTS $VRX
— zach (@zbiotech) March 10, 2016
"$EDIT be crazy" (Wild ride for Editas)
$EDIT coverage initiation - Neutral at JP Morgan, Equalweight at Morgan Stanley, Outperform at Cowen.
— Bio Stocks™ (@BioStocks) February 29, 2016
$EDIT now has a $1 Billion market cap. PreClinical.
— Dan Smithey (@dan_smithey) March 1, 2016
@adamfeuerstein What do you think of $EDIT (+17% $37 today)? I feel like it's going to be the next $BLUE...
— Jean Fonteneau (@JFinDallas) March 3, 2016
$edit hit intraday high of $41.60 ... MC now $1.4B
— vlad33301 (@vlad33301) March 7, 2016
$EDIT EV now ~$1.3B, higher than $BLUE, ~2X of $ONCE, ~10X of $QURE
— Andy Biotech (@AndyBiotech) March 8, 2016
the new way to play #biotech is buy $EDIT short everything else
— Dan Rosenblum (@sharkbiotech) March 9, 2016
$EDIT Relies on Friends for Post-IPO Stock Boom https://t.co/GpIaC0OcAi Low float, no borrow helping post-IPO stock performance.
— Adam Feuerstein (@adamfeuerstein) March 9, 2016
$EDIT when holding the bag always remember blame @adamfeuerstein LOL
— Nathan Michaud (@InvestorsLive) March 9, 2016
$EDIT more like abandon ship mode now... pic.twitter.com/9GwXvVnU7v
— Jean Fonteneau (@JFinDallas) March 9, 2016
$EDIT be crazy
— Stan D'Andrea (@stanleydandrea) March 11, 2016
Celldex cancer vaccine flops in glioblastoma $CLDX
$CLDX DSMB Recommends Phase 3 Study Of RINTEGA To Be Discontinued As It Is Unlikely To Meet Primary Overall Survival Endpoint
— Bio Stocks™ (@BioStocks) March 7, 2016
$CLDX Rintega “ACT IV” ph3 brain tumor study stopped for futility at interim analysis. I had hope for this one, but not to be. Fail.
— Adam Feuerstein (@adamfeuerstein) March 7, 2016
What a shame about Rintega. Unlike just about anyone else $CLDX had actually managed to design a robust glioblastoma study.
— Jacob Plieth (@JacobPlieth) March 7, 2016
Add $CLDX to the list of bios trading below cash.
— PropThink (@PropThinker) March 7, 2016
$CLDX what a bummer
— Brad Loncar (@bradloncar) March 7, 2016
$CLDX down 60%-plus -- never bet on a cancer vaccine. https://t.co/TRAQRjYNPi
— John Carroll (@JohnCFierce) March 7, 2016
$CLDX..$3.50 in pre-mkt here. Chart action said it all the past few months. Bounce play possibility.
— Sheff (@SheffStation) March 7, 2016
$CLDX is (was) 100% 'buy-rated' by the sell side
— zach (@zbiotech) March 7, 2016
$CLDX another trial where control arm significantly out-performed. assumption was 16 month OS
— Red Acre Investments (@redacre) March 7, 2016
LR $CLDX Downgrading to MP after disappointing Rintega failure in ACT IV; PT to Price Target: $30.00 → $4.00
— dough (@tgtxdough) March 9, 2016
After long wait, Sarepta has a new Advisory Committee date $SRPT
$SRPT confirms 30 layoffs in consolidation.https://t.co/gmFcXNXilS
— John Carroll (@JohnCFierce) March 9, 2016
As we wait, FDA spox affirms to me that $SRPT adcomm was “postponed” not cancelled. Won’t say more about efforts to reschedule.
— Adam Feuerstein (@adamfeuerstein) March 9, 2016
$SRPT increases "operational efficiency" through facility consolidation as negative sentiment increases for #DMD drug - no new meeting date
— Lisa LaMotta (@BioWriterChik) March 9, 2016
$SRPT FDA PCNS AdCom rescheduled for 4/25/16
— Andy Biotech (@AndyBiotech) March 10, 2016
$SRPT FDA adcomm on April 25 comes 3 years after company annc’d accelerated approval filing plan. Remember that? https://t.co/H7huUGzWHM
— Adam Feuerstein (@adamfeuerstein) March 10, 2016
$SRPT up 15% on an adcom date?
— John Carroll (@JohnCFierce) March 10, 2016
Puh-leeze, people. What are you drinking?
I don't think $SRPT has confirmed the adcom yet via PR
— j l (@bio_clouseau) March 11, 2016
As seen on the stream
Amazing $ACAD PR has no mention of 03/29 FDA adcom at all!
— Andy Biotech (@AndyBiotech) February 29, 2016
$HRTX delay again. When companies don't meet their dates, investors need to take notice.
— Sheff (@SheffStation) February 29, 2016
$ONTY Oncothyreon Commences ONT-380 Combo Phase 2 Dosing in HER2-Positive Breast Cancer
— BioBreakout (@BioBreakout) February 29, 2016
On #RareDiseaseDay, reminding you all of some great parents & advocates to follow: @savingcase @JJB4CURE @HHF4GAN @collabchem @eperlste
— Lisa Jarvis (@lisamjarvis) February 29, 2016
Fidelity with a 25% writedown for Moderna, 37% for Stemcentrx- https://t.co/CpIabesf0s
— Vikram Khanna (@VikramKhanna_) February 29, 2016
Just made the mistake of the night checking out the $RLYP stream.
— 23Chromz (@23Chromz) March 1, 2016
.@Sport234a Have to kudos again to those mgnt teams who managed to sell around the peak last yr! $PCYC$GEVA$RCPT$DYAX$ASPX$ZSPH
— Andy Biotech (@AndyBiotech) March 1, 2016
The market considering $RLYP $FGEN $AKBA $AUPH as sympathy plays for $RMTI is so far from making any sense...
— NSharma (@Sharma1981N) March 1, 2016
Downgrades galore in Biotech today. Sell Side trying to hold on to some credibility
— Dan Smithey (@dan_smithey) March 1, 2016
@DrPaulyDeSantis @AndyBiotech Still any multiple cannot be broad brushed as some sectors such as IO deserves higher.
— Raj R (@rajramaswamy) March 1, 2016
$JUNO $KITE took off maybe #biotech shorts begin to get a bit nervous
— Dan Rosenblum (@sharkbiotech) March 1, 2016
If bios weren't so out of favor I would be pounding the table on $FGEN right now. added small amount under 17 (10% pos)
— Olddogwithnewtrix (@olddoggnewtrix) March 1, 2016
@biotrader4gain Still down 43% from the peak $XBI
— Sudhanva Raj (@SudhanvaRaj) March 2, 2016
Syndax Pharmaceuticals prices IPO at $12, well below the range $SNDX $IPO #IPO https://t.co/edDRJylg5G
— Renaissance Capital (@IPOtweet) March 2, 2016
. @shaneblackmon Likely giving people a chance to exit before more sideways to down action in summer and fall.
— Shane Blackmon (@shaneblackmon) March 3, 2016
Paul Cuddon at Numis initiating on $GWPH with a SELL rating, target is like $2.50 US You don't say, First analyst that gets it :)
— Marc Lehman (@markflowchatter) March 3, 2016
$SGEN Baker Bros. add 675K shares.
— Bio Stocks™ (@BioStocks) March 3, 2016
I just realized what's powering the biotech comeback. It's not Sanders' defeats. It's quarterly CC's and balance sheets.
— Tony Friedman (@zzlangerhans) March 3, 2016
three strikes you're out right? or is that 4? or 5? sheesh$VTAE
— Paul D. Rennert (@PDRennert) March 4, 2016
Some really great reads from my friends at BBG this wk! $JUNO's original name was FC Therapeutics, for "f*ck cancer" https://t.co/KIt5bZvble
— Meg Tirrell (@megtirrell) March 4, 2016
Biotech has its first week of positive fund flows in 2016, according to Raymond James; inflows of $81m for wk ending March 2
— Meg Tirrell (@megtirrell) March 4, 2016
New immunotherapy discovery could give treatments the precision they need https://t.co/TDM6RMLucj
— Olddogwithnewtrix (@olddoggnewtrix) March 4, 2016
See so many biopharma ads on my stream now. Is this because @twitter finally figured out target ads or biopharma just step up ad campaign?
— JQ (@jq1234t) March 5, 2016
Jimmy Carter No Longer Needs Cancer Treatments Thanks To Promising Immunotherapy Drug https://t.co/htNr0mc57h
— Brad Loncar (@bradloncar) March 7, 2016
"Reversing aging in humans is plausible" George Church at a science conference on Thursday https://t.co/2NlZXyiaHJ HT @jflier @JohnNosta
— Daphne Zohar (@daphnezohar) March 7, 2016
so has R&D productivity under or outperformed contol/placebo responses over the last several years?
— zach (@zbiotech) March 7, 2016
Four of the worst words in clinical development: "Control arm outperformed expectations". $CLDX
— Bruce Booth (@LifeSciVC) March 7, 2016
$AMGN CFO: "The hardest thing to do when you have money in the bank is to be disciplined" -- story on @business terminal.
— Caroline Chen (@CarolineYLChen) March 7, 2016
$ZFGN could go higher here, I just don't like the idea that they can be finished with 1 more setback.
— BioBounce.com (@BioBounce) March 7, 2016
$EDIT --> The high-profile #CRISPR patent case between Berkeley and Broad will also start tomorrowhttps://t.co/xMYfEM2kCh
— Andy Biotech (@AndyBiotech) March 8, 2016
Theranos, man. Theranos.
— Charley Grant (@CGrantWSJ) March 8, 2016
Pfizer Commences $5 Billion Accelerated Share Repurchase $PFE https://t.co/b4RdzkS3vy
— David Sobek (@dsobek) March 9, 2016
$AKBA Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat - EPO revoked $FGEN '823 patent in its entirety
— zach (@zbiotech) March 9, 2016
With CMS Medicare Part B test proposal analysts say: $REGN, $AMGN, $BIIB exposure; AMGN (Neupogen, Neulasta, Kyprolis); CELG (Abraxane)
— Sasha Damouni Ellis (@SashaDamouni) March 9, 2016
Sold $FGEN $12.50 Sept puts at $2.
— NSharma (@Sharma1981N) March 9, 2016
— Stan D'Andrea (@stanleydandrea) March 9, 2016
$BLUE Nick hedges on regulatory timing for SCD and Thal - ongoing discussions with regulators. Specifics haven’t changed - data dependent.
— CGB3 Beck (@princetongb) March 9, 2016
$jpm raised PT's 4 $gild $aria $ceru. Cut PT's for $mdgn $pfnx $cytk $cnce $bomc $cgen $cbyl $cala $atra $bind $blrx $args $ardx $alny $akba
— Joe (@Drchik23) March 9, 2016
Team @ShileyEyeUCSD repairs cataracts using lens made from patients' own #stemcells via @nature @guardianscience https://t.co/09S7DOYAv8
— CIRM (@CIRMnews) March 9, 2016
Secured a bit of profit in $OMER (kept core intact)@$16&added some $BLCM@$9.40. Need BLCM ER to reinforce ACT onc. prgrms all on-schedule.
— Jason (@JasonHolman5) March 9, 2016
@pawcio2009 everything thats presenting is getting bad $blue $rare. $opht
— Big Chodu (@BigChodu) March 9, 2016
the good news is that we are only 4 #ECB meetings from #Draghi buying #biotech stocks
— Dan Rosenblum (@sharkbiotech) March 10, 2016
Maybe $IDRA’s DMD program is the first to be dropped after seeing how unfriendly regulators have been in this area? https://t.co/NwgVAz7Vbu
— Brad Loncar (@bradloncar) March 10, 2016
28.7% of all tickers in $IBB $XBI $SBIO $BBC $BBP are above their 50ma.
— BioBounce.com (@BioBounce) March 10, 2016
$TRIL Trillium Announces a $3.4 Million Government Co-Funded Translational Research Program https://t.co/gE1RQOe67S
— Joe (@GantosJ) March 10, 2016
Dinosaurs $VCEL and $XOMA re-animated this AM. It's like Jurassic Park. pic.twitter.com/4o46MwD6lG
— Jake King (@FajaJake) March 10, 2016
@Biotech_5 no one really cares about it one way or the other really. They need to keep working. $qure
— Adam Singer (@AdamSinger) March 10, 2016
. @JFinDallas Thinking same thing. Once again, $AVXL resorts to scientific malpractice in order to promote its stock price.
— Adam Feuerstein (@adamfeuerstein) March 10, 2016
CAR T etc getting lots of bad press. I think the potential was overhyped last year but I also think the challenges are being overhyped now.
— Paul D. Rennert (@PDRennert) March 10, 2016
@Mazmasta pretty much a tell when all the buying of $SGEN by Baker Bros can't move the name, although rs vs. biotech as a whole.
— Tom Wrigley (@WrigleyTom) March 10, 2016
@WrigleyTom yeah but $INCY, their top holding, looks like... well... shit.
— E B (@Mazmasta) March 10, 2016
$BIIB ooops EU Court Revokes Tecfidera's 480mg Dose Patent
— Andy Biotech (@AndyBiotech) March 10, 2016
Jennifer Doudna 030916 @StanfordMed #CRISPR Talk: Quick Thots $EDIT #Caribou
— Dr. Zoidberg (@psuvafan007) March 11, 2016
Read: https://t.co/dHotqHktFM
@sciencescanner reminds me of US media hyping a study abt strawberries & cancer - n=12 Chinese & freeze dried - protect you from cancer!
— Sally Church (@MaverickNY) March 11, 2016
I am walking in NYC and randomly a researcher at $BLUE recognized me and said hello. Said they're happy to be treating patients with CART.
— Brad Loncar (@bradloncar) March 11, 2016
$JNJ has increased the price of Remicade by 4.9% this week prior to upcoming $PFE/Celltrion #biosimilar approval. CC @biosimilarz
— Andy Biotech (@AndyBiotech) March 11, 2016
Well that turned around quickly. After 1 rare + wk, biotech fund flows turn negative again, according to Raymond James: -$288m wk ending 3/9
— Meg Tirrell (@megtirrell) March 11, 2016
CantorF:" $CARA Many Clinical Irons in the Fire, Some Clarity Needed Around IV Pain Timelines, TP=$28..."
— Tom Silver (@TomSilver39) March 11, 2016
@princetongb We’re overdue for a jaw-dropping surprise of a good trial result.
— Brad Loncar (@bradloncar) March 11, 2016
My preschooler this morning: "It's SO hard to be a scientist when your bedtime is 8pm."
— Lisa Jarvis (@lisamjarvis) March 3, 2016